SBIR/STTR Research Award
Polaris EECD: Improving Patient Engagement in Chemically Dependent Adults- Phase
Award amount
$1,162,573Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- POLARIS HEALTH DIRECTIONS, INC
- Proposal award date
- 2014-04-01
- Contract end date
- 2016-01-31
- UEI
- Not reported
- Solicitation number
- PA13-234
- Topic code
- NIDA
Research abstract
DESCRIPTION provided by applicant Full engagement is essential for positive outcomes in addiction treatment Evidence based practices EBPs for enhancing treatment engagement include Motivational Interviewing Enhancement Therapy MI MET and andquot Matchingandquot patient services to patient needs Their adoption in routine clinical practice has been hindered by the inefficient methods available for introducing these practices Information technology will play an important role in overcoming this barrier Polaris Engagement Enhancement in Chemical Dependency EECD is a web based system developed and field tested in Phase It consists of a web based HIPAA compliant IT platform and comprehensive assessment outcomes management and clinical reporting software Phase innovations of a personalized client feedback report and the first multivariable model for prediction of non engagement available for use in clinical practice enhanced the overall system capability EECD represents the first technology designed to facilitate the use of MI MET and andquot Matching andquot The Phase Specific Aims are to strengthen the clinical utility and commercial potential of EECD through enhancements suggested by the field test and integrate EECD with a market leading electronic health record Epic enhance implementation materials developed in Phase by producing a training video establish a network of trainers expert in both MI MET and the use of EECD reports for MI MET and Matching and develop an Implementation Tool Kit and conduct a controlled clinical trial to evaluate the effectiveness of EECD for improving engagement and clinical outcomes and reducing rates of treatment re entry Phase will make a significant clinical and research contribution The products of this translational research include clinical tools that will exert a sustained powerful impact on the field through increasing the adoption of EBPs that have been shown to improve treatment engagement and clinical outcomes Polaris EECD will have strong commercial potential Markets will include CD treatment programs and Accountable Care Organizations In Phase Polaris will self fund a version of EECD designed for use in medical settings PUBLIC HEALTH RELEVANCE This proposal addresses an important problem for addictions treatment Of clients that initiate treatment approximately do not engage and they drop out within a month The consequences in terms of human suffering and economic burden on public agencies are great Non engagement is associated with increased drug use criminal activity and reduced employment status The proposed Polaris Engagement Enhancement for Chemical Dependency system will combine state of the art information technology with evidence based practices for improving engagement and an innovative model for predicting risk for non engagement It will impact public health by improving engagement and clinical outcomes and contribute to research on factors predictive of engagement for demographically diverse clients
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)